Luo Jingfeng, Wu Xiaotian, Zhou Fei, Zhou Yurong, Huang Tongchun, Liu Fei, Han Guocan, Chen Luming, Bai Weixian, Wu Xia, Sun Jihong, Yang Xiaoming
Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Image-Guided Bio-Molecular Intervention Research, Department of Radiology, University of Washington School of Medicine, Seattle, Washington, USA.
Oncotarget. 2016 Oct 4;7(40):65042-65051. doi: 10.18632/oncotarget.11346.
Gene therapy is a frontier in modern medicine. In the present study, we explored a new technique for the effective treatment of multidrug-resistant (MDR) breast cancer by combining fully the advantages of multidisciplinary fields, including image-guided minimally invasive interventional oncology, radiofrequency technology, and direct intratumoral gene therapy.
Combination treatment with PHSP-TK plus RFH resulted in significantly higher TK gene transfection/expression, as well as a lower cell proliferation rate and a higher cell apoptosis index, than those of control groups. In vivo validation experiments with MRI confirmed that combination therapy resulted in a significant reduction of relative tumor volume compared with those of control animals, which was supported by the results of histologic and apoptosis analyses.
The heat shock protein promoter (PHSP) was used to precisely control the overexpression of thymidine kinase (TK) (PHSP-TK). Serial in vitro experiments were performed to confirm whether radiofrequency hyperthermia (RFH) could enhance PHSP-TK transfection and expression in a MDR breast cancer cell line (MCF7/Adr). Serial in vivo experiments were then carried out to validate the feasibility of the new technique, termed interventional RFH-enhanced direct intratumoral PHSP-TK gene therapy. The therapeutic effect of combination therapy was evaluated by MRI and confirmed by subsequent laboratory correlation.
This study has established "proof-of-principle" of a new technique, interventional RFH-enhanced local gene therapy for MDR breast cancer, which may open new avenues for the effective management of MDR breast cancers via the simultaneous integration of interventional oncology, RF technology, and direct intratumoral gene therapy.
基因治疗是现代医学的前沿领域。在本研究中,我们充分结合多学科领域的优势,包括影像引导下的微创介入肿瘤学、射频技术和直接瘤内基因治疗,探索一种有效治疗多药耐药(MDR)乳腺癌的新技术。
与对照组相比,PHSP-TK联合RFH治疗导致显著更高的TK基因转染/表达,以及更低的细胞增殖率和更高的细胞凋亡指数。MRI体内验证实验证实,与对照动物相比,联合治疗导致相对肿瘤体积显著减小,组织学和凋亡分析结果支持这一点。
利用热休克蛋白启动子(PHSP)精确控制胸苷激酶(TK)(PHSP-TK)的过表达。进行一系列体外实验,以确认射频热疗(RFH)是否能增强PHSP-TK在多药耐药乳腺癌细胞系(MCF7/Adr)中的转染和表达。随后进行一系列体内实验,以验证这种称为介入性RFH增强直接瘤内PHSP-TK基因治疗的新技术的可行性。通过MRI评估联合治疗的疗效,并通过后续实验室相关性进行确认。
本研究确立了一种新技术的“原理证明”,即介入性RFH增强的多药耐药乳腺癌局部基因治疗,这可能通过同时整合介入肿瘤学、RF技术和直接瘤内基因治疗,为有效管理多药耐药乳腺癌开辟新途径。